TLR3 and metastatic melanoma: The adjuvant CAF09b, composed of dimethyldioctadecylammonium (DDA), the MINCLE agonist monomycoloyl glycerol (MMG) and the TLR3 agonist Poly(I:C), is effective at inducing CD8 T cell responses and is currently tested in neoepitope peptide-based vaccines against metastatic melanoma in humans.32